RCS - hVIVO PLC - Presentation at Jefferies Healthcare Conference

hVIVOAnnouncement

03/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC7369Fa&default-theme=true

RNS Number : 7369F  hVIVO PLC  03 November 2025

 

hVIVO plc

("hVIVO" or the "Company")

 

hVIVO to present at Jefferies Global Healthcare Conference

 

hVIVO plc (AIM: HVO), a full-service early phase Contract Research
Organisation (CRO) and the world leader in human challenge clinical trials,
announces that Yamin 'Mo' Khan, Chief Executive Officer, will be presenting
in-person at the Jefferies Global Healthcare Conference in London on 20
November 2025 at 12.30pm GMT. Alongside the presentation, the Company will
also be available for one-to-one meetings.

 

The Jefferies Global Healthcare Conference is the largest healthcare-dedicated
conference in Europe and is taking place between the 17-20 November 2025 in
London. The conference hosts over 700 healthcare companies, 3,600 attendees,
and 10,000 investor and business-to-business meetings. The event brings
together C-suite executives from leading public and private companies from the
pharmaceuticals, biotechnology, medical technology, and healthcare services
sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.

 

No new material information will be disclosed during the day and the PDF of
the presentation will be made available on the Company's website shortly after
the event.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson,

 Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings /                 +44 (0)7980 541 893 / +44 (0)7407 804 654/

 Lianne Applegarth                               +44 (0)7584 391 303

 

 

Notes to Editors

 

hVIVO plc
(https://protect.checkpoint.com/v2/___https:/hvivo.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjpjNDgxOmZkYjBmOGQ2NmIyOTcwNDJmNGJkZjFkOWVmYzI1MmE2OGEwMTdmMjMzNTQ4YWVlYTg1YjgzZjAwZmJkMzc0NGE6cDpUOk4)
(Ticker: HVO) is full-service early phase Contract Research Organisation (CRO)
and the global leader in human challenge trials. The company delivers
end-to-end clinical development services to a diverse and expanding client
base, including seven of the world's ten largest biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB
(https://protect.checkpoint.com/v2/___https:/hlabservices.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6Njo4NDI3OjM4YzRiNDBkMjg4Mzk2M2IzMjNlYzgyYzY5OGY4NzE1ODU1NTc3MjVlODdmNzcxMjQwNDNmOWE1MzI4ZDhkYmM6cDpUOk4)
brand.

 

Through its German subsidiary, CRS
(https://protect.checkpoint.com/v2/___https:/crs-earlyphase.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjoyNmIxOmYzN2ZiOTAzYjYzMWFmMmVjNDA2OTY3NzVmODg5NmQ2NTlmZmNkMzgxMTcxNDNmYzBlMGYxMDE2NGMyNjE5NDA6cDpUOk4)
, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing
early-phase clinical trial services, including first-in-human and
proof-of-concept studies. Its second subsidiary, Venn Life Sciences
(https://protect.checkpoint.com/v2/___https:/www.vennlifesciences.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjplYTdmOjgzYmE4NThiMzYyYmNiNzg5ZmU0ZDcwZWMzZmE1YTZmZDMxODRkY2NiZWZjOWNmNjM3ODhmYTUzNmQxNjI3Mzk6cDpUOk4)
, offers Early Drug Development Consulting and Biometry services to the
biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp
(https://protect.checkpoint.com/v2/___https:/flucamp.com/___.YzJ1OmNpZGFyYXRoZXJhcGV1dGljczpjOm86NGI1ZTVkN2YwOWEyMzA2MjNkMTUzZDc0ZGY1MmIyODk6NjplMjk5OjY1ODkxMWUxZGNkOWY1ZjQxOTc1NDM0NDUxNGFmMGI5MWQyZTc4ZmQ1MWVlZWU5ZjdkZTlhOGY0NWQ2ZDJiNGY6cDpUOk4)
. Additionally, its five clinical sites support outpatient Phase II and III
trials, ensuring a seamless and efficient pathway from discovery to late-stage
development.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABDBDGLXXDGUB



            Copyright 2019 Regulatory News Service, all rights reserved